Antisense oligodesoxynucleotide strategies in renal and cardiovascular disease

Kidney International

Volumn 53, Issue 6, 1998, Pages 1550-1558

  Haller, Hermann ^a,b   Maasch, Christian ^a   Dragun, Duska ^a   Wellner, Maren ^a   Von Janta Lipinski, Michael ^a   Luft, Friedrich C ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b FRANZ VOLHARD CLINIC   (Germany)

Author keywords

Acute renal failure; Adhesion molecules; Antisense; Endothelium; Gene transfer; Oligodesoxynucleotides; Protein kinase C

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CELL ADHESION MOLECULE; INTERCELLULAR ADHESION MOLECULE 1; PHOSPHOROTHIOIC ACID; PROTEIN KINASE C; VIRUS FUSION PROTEIN;

ACUTE KIDNEY FAILURE; BONE STRUCTURE; CARDIOVASCULAR DISEASE; CONFERENCE PAPER; ENDOTHELIUM; ENZYME ACTIVITY; GENE TRANSFER; HUMAN; KIDNEY GRAFT; PRIORITY JOURNAL; REPERFUSION INJURY; RNA TRANSCRIPTION; SIGNAL TRANSDUCTION; TARGET CELL;

EID: 0031782465     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.1998.00927.x     Document Type: Conference Paper

References (53)

1. ZAMECNIK PC, STEPHENSON ML: Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Aca Sci 75:280, 1978
2. CROOKE ST, LEBLEU B: Antisense Research and Applications. Boca Raton, Fl, CRC Press, 1993
3. HEIDENREICH O, GRYAZNOV S, NERENBERG M: RNase H-independent antisense activity of oligonucleotide N3-P5′ phosphoramidates. Nucleic Acids Res 25:776-780, 1997
4. WILSON WD, MIZAN S, TANIOUS FA, YAO S, ZON G: The interaction of intercalators and groove-binding agents with DNA triple-helical structures: The influence of ligand structure, DNA backbone modifications and sequence. J Mol Recog 7:89-98, 1994
5. UHLMANN E, PEYMAN A: Oligonucleotide analogs containing dephospho-internucleoside linkages. Methods Mol Biol 20:355-389, 1993
6. CHEN JK, SCHULTZ RG, LLOYD DH, GRYAZNOV SM: Synthesis of oligodeoxy-ribonucleotide N3′→P5′ phosphoramidates. Nucleic Acids Res 23:2661-2668, 1995
7. GRYAZNOV SM, LLOYD DH, CHEN JK, SCHULTZ RG, DEDIONISIO LA, RATMEYER L, WILSON DW: Oligonucleotide N3′→P5′ phosphoramidates. Proc Natl Acad Sci USA 92:5798-5802, 1995
8. ESCUDE C, GIOVANNANGELI C, SUN JS, LLOYD DH, CHEN JK, GRYAZNOV SM, GARESTIER T, HELENE C: Stable triple helices formed by oligonucleotide N3→P5′ phosphoramidates inhibit transcription elongation. Proc Natl Acad Sci USA 93:4365-4369, 1996
9. GRYAZNOV SM, SKORSKI T, CUCCO C, NIEBOROWSKA-SKORSKA M, CHIU CY, CHEN JK, KOZIOLKIEWICZ M, CALABRETTA B OLIGONUCLEOTIDE N3→P5′ phosphoramidates as antisense agents. Proc Natl Acad Sci USA 92:5798-802, 1997
10. 31P NMR spectroscopy in oligonucleotide research and development. Antisense Nucleic Acid Drug Dev 7:55-61, 1997
11. FINKEL T, EPSTEIN SE: Gene therapy for vascular disease. FASEB J 9:843-851, 1995
12. NISHIZUKA Y: Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science 258:607-614, 1993
13. DEISHER TA, HADDIX TL, MONTGOMERY KF, POHLMAN TH, KAUSHANSKY K, HARLAN JM: The role of protein kinase C in the induction of VCAM-1 expression on human umbilical vein endothelial cells. FEBS Lett 331:285-290, 1993
14. KUCHAN MJ, FRANGOS JA: Shear stress regulates endothelin-1 release via protein kinase C and cGMP in cultured endothelial cells. Am J Physiol 264:H150-H156, 1993
15. BLUME-JENSEN P, SIEGBAHN A, STABEL S, HELDIN CH, RONNSTRAND L: Increased Kit/SCF receptor induced mitogenicity but abolished cell motility after inhibition of protein kinase C. EMBO J 12:4199-4209, 1993
16. ZHOU W, TAKUWA N, KUMADA M, TAKUWA Y: Protein kinase C-mediated bidirectional regulation of DNA synthesis, RB protein phosphorylation, and cyclin-dependent kinases in human vascular endothelial cells. J Biol Chem 268:23041-23048, 1993
17. BUSUTTIL SJ, MOREHOUSE DL, YOUKEY JR, SINGER HA: Antisense suppresssion of protein kinase C-alpha and -delta in vascular smooth muscle. J Surg Res 63:137-142, 1996
18. KLEUSS C, HESCHELER J, EWEL C, ROSENTHAL W, SCHULTZ G, WITTIG B: Assignment of G-protein subtypes to specific receptors inducing inhibition of calcium currents. Nature 353:43-48, 1991
19. ABE J, ZHOU W, TAGUCHI J, TAKUWA N, MIKI K, OKAZAKI H, KUROKAWA K, KUMADA M, TAKUWA Y: Suppression of neointimal smooth muscle cell accumulation in vivo by antisense cdc2 and cdk2 oligonucleotides in rat carotid artery. Biochem Biophys Res Commun 198:16-24, 1994
20. NAKAJIMA T, KITAJIMA I, SHIN H, TAKASAKI I, SHIGETA K, ABEYAMA K, YAMASHITA Y, TOKIOKA T, SOEJIMA Y, MARUYAMA I: Involvement of NF-kappa B activation in thrombin-induced human vascular smooth muscle cell proliferation. Biochem Biophys Res Commun 204:950-958, 1994
21. ALI S, DAVIS MG, BECKER MW, DORN GWD: Thromboxane A2 stimulates vascular smooth muscle hypertrophy by up-regulating the synthesis and release of endogenous basic fibroblast growth factor. J Biol Chem 268:17397-17403, 1993
22. MORRISON RS, YAMAGUCHI F, SAYA H, BRUNER JM, YAHANDA AM, DONEHOWER LA, BERGER M: Basic fibroblast growth factor and fibroblast growth factor receptor I are implicated in the growth of human astrocytomas. J Neurooncol 18:207-216, 1994
23. MARTINY BARON G, MARME D: VEGF-mediated tumour angiogenesis: A new target for cancer therapy. Curr Opin Biotechnol 6:675-680, 1995
24. CIERNIEWSKI CS, BABINSKA A, SWIATKOWSKA M, WILCZYNSKA M, OKRUSZEK A, STEC WJ: Inhibition by modified oligodeoxynucleotides of the expression of type-1 plasminogen activator inhibitor in human endothelial cells. Eur J Biochem 227:494-499, 1995
25. DUCHOSAL MA, ROTHERMEL AL, MCCONAHEY PJ, DIXON FJ, ALTIERI DC: In vivo immunosuppression by targeting a novel protease receptor. Nature 380:352-356, 1996
26. USHIO FUKAI M, ZAFARI AM, FUKU T, ISHIZAKA N, GRIENDLING KK: p22phox is a critical component of the superoxide-generating NADH NADPH oxidase system and regulates angiotensin II-induced hypertrophy in vascular smooth muscle cells. J Biol Chem 271:23317-23321, 1996
27. WOLF G, SCHROEDER R, ZIYADEH FN, THAISS F, ZAHNER G, STAHL RA: High glucose stimulates expression of p27Kipl in cultured mouse mesangial cells: Relationship to hypertrophy. Am J Physiol 273(3 Pt 2):F348-F356, 1997
28. FINE LG: Gene transfer into the kidney: Promise for unravelling disease mechanisms, limitations for human gene therapy. Kidney Int 49:612-619, 1996
29. BEVILACOUA MP, NELSON RM, MANNORI G, CECCONI O: Endothelial-leukocyte adhesion molecules in human disease. Annu Rev Med 45:361-378, 1994
30. BONVENTRE J: Mechanisms of ischemic acute renal failure. Kidney Int 43:1160-1178, 1993
31. BUTCHER EC: Leukocyte-endothelial cell recognition: Three (or more) steps to specificity and diversity. Cell 67:1033-1036, 1991
32. RABB H, MENDIOLA CC, DIETZ J, SABA SR, ISSEKUTZ TB, ABANILLA F, BONVENTRE JV, RAMIREZ G: Role of CD11a and CD11b in ischemic acute renal failure in rats. Am J Physiol 267:F1052-F1058, 1994
33. KELLY KJ, WILLIAMS W, COLVIN RB, BONVENTRE JV: Antibody to intracellular adhesion molecule 1 protects the kidney against ischemic injury. Proc Natl Acad Sci USA 91:812-816, 1994
34. IOCULANO M, SQUADRITO F, ALTAVILLA D, CANALE P, SQUADRITO G, CAMPO GM, SAITTA A, CAPUTI AP: Antibodies against intercellular adhesion molecule 1 protect against myocardial ischaemia-reperfusion injury in rat. Eur J Pharmacol 264:143-149, 1994
35. CHIANG MY, CHEN H, ZOUNES MA, FREIER SM, LIMA WF, BENNETT CF: Antisense oligonucleotides inhibit intercellular adhesion molecule-1 expression by two distinct mechanisms. J Biol Chem 266:18161-18174, 1991
36. STEPKOWSKI S, TU Y, CONDON TP, BENNETT CF: Blocking of heart allograft rejection by intracellular adhesion molecule-1 antisense oligonueleotides alone or in combination with other immunosuppressive modalities. J Immunol 153:5336-5346, 1994
37. TILNEY NL, WHITLEY WD, DIAMOND JR. KUPIEC-WEGLINSKI JW, ADAMS DH: Chronic rejection-An undefined conundrum. Transplantation 52:389-398, 1991
38. HEEMANN U, TULIUS SG, SCHUMANN V, TILNEY NL: Neutrophils and macrophages are prominent in the pathophysiology of chronic rejection of rat kidney allografts. Transplant Proc 25:937-938, 1993
39. HILL P, MAIN IW, ATKINS RC: ICAM-1 and VCAM-1 in human renal allograft rejection. Kidney Int 47:1383-1391, 1995
40. UTHOFF K, ZEHR KJ, LEE PC, Low RA, BAUMGARTNER WA, CAMERON DE, STUART RS: Neutrophil modulation results in improved pulmonary function after 12 and 24 hours of preservation. Ann Thorac Surg 59:7-12, 1995
41. NEWMAN KD, DUNN PF, OWENS JW, SCHULICK AH, VIRMANI R, SUKHOVA G, LIBBY P, DICHEK DA: Adenovirus-mediated gene transfer into normal rabbit arteries results in prolonged vascular cell activation, inflammation, and neointimal hyperplasia. J Clin Invest 96:2955-2965, 1995
42. NABEL EG, PLAUTZ G, NABEL GJ: Site-specific gene expression in vivo by direct gene transfer into the arterial wall. Science 249:1285-1288, 1990
43. NABEL EG, POMPILI VJ, PLAUTZ GE, NABEL GJ: Gene transfer and vascular disease. Cardiovasc Res 28:445-455, 1994
44. FINKEL T, EPSTEIN SE: Gene therapy for vascular disease. FASEB J 9:843-851, 1995
45. KANEDA Y, UCHIDA T, KIM J, ISHIURA M, OKADA Y: The improved efficient method for introducing macromolecules into cells using HVJ (Sendai virus) liposomes with gangliosides. Exp Cell Res 173:56-69, 1987
46. KANEDA Y, IWAI K, UCHIDA T: Introduction and expression of the human insulin gene in adult rat liver. J Biol Chem 264:12126-12129, 1989
47. MORISHITA R, GIBBONS GH, KANEDA Y, OGIHARA T, DZAU VJ: Novel and effective gene transfer technique for study of vascular renin angiotensin system. J Clin Invest 91:2580-2585, 1993
48. VON DER LEYEN HE, GIBBONS GH, MORISHITA R, LEWIS NP, ZHANG L. NAKAJIMA M, KANEDA Y, COOKE JP, DZAU VJ: Gene therapy inhibiting neointimal vascular lesion: In vivo transfer of endothelial cell nitric oxide synthase gene. Proc Natl Acad Sci USA 92:1137-1141, 1995
49. MORISHITA R, GIBBONS GH, ELLISON KE, NAKAJIMA M, VON DER LEYEN H, ZHANG L, KANEDA Y, OGIHARA T, DZAU VJ: Intimal hyperplasia after vascular injury is inhibited by antisense cdk 2 kinase oligonucleotides. J Clin Invest 93:1458-1464, 1994
50. MORISHITA R, GIBBONS GH, HORIUCHI M, ELLISON KE, NAKAMA M, ZHANG L, KANEDA Y, OGIHARA T, DZAU VJ: A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proc Natl Acad Sci USA 92:5855-5859, 1995
51. YEAGLE P: The fusion of Sendai virus. Boca Raton, 1993, pp 313-334
52. OKADA Y: Sendai virus-induced cell fusion. Methods Enzymol 221:18-41, 1993
53. PONIMASKIN E, VEIT M, SCHMIDT MF: Expression of the Sendai virus fusion protein in insect cells and characterization of its post-translational modifications. J Gen Virol 75:1163-1167, 1994